Antibiotic Portfolio
Bacterial Infections
Approved/CommercialMarketed
Key Facts
About SPIMACO
SPIMACO is a major player in the Saudi and MENA region pharmaceutical market, established to enhance local drug manufacturing capabilities and ensure medicine security. The company operates multiple manufacturing facilities and has a diverse portfolio spanning various therapeutic areas, including cardiology, gastroenterology, and antibiotics. As a publicly listed entity, it plays a strategic role in the Saudi Vision 2030 goals for healthcare self-sufficiency, combining local production with technology transfer from international partners.
View full company profileTherapeutic Areas
Other Bacterial Infections Drugs
| Drug | Company | Phase |
|---|---|---|
| Novel Antibiotics | Shionogi | Various |
| Anti-infectives Portfolio | Aurobindo Pharma | Commercial |
| Azithromycin products | Alkem Laboratories | Commercial |
| Cefixime & Ofloxacin combinations | Ipca Laboratories | Commercial |
| Zevtera® (ceftobiprole medocaril) | Basilea Pharmaceutica | Approved/Commercial |
| Cephalosporin APIs (Cefixime, Cefpodoxime, etc.) | Nectar Lifesciences | Approved |
| Penicillin APIs (Amoxicillin, etc.) | Nectar Lifesciences | Approved |
| Vibativ® (telavancin) | Cleo Life Sciences | Approved |